Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AEGR

AEGR (AEGR) Stock Price, News & Analysis

AEGR logo

About AEGR Stock (NASDAQ:AEGR)

Advanced Chart

Key Stats

Today's Range
$1.97
$1.97
50-Day Range
$1.97
$1.97
52-Week Range
$1.23
$10.85
Volume
N/A
Average Volume
635,262 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

Receive AEGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AEGR and its competitors with MarketBeat's FREE daily newsletter.

AEGR Stock News Headlines

Hedge Fund - Glenhill Advisors
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

AEGR Stock Analysis - Frequently Asked Questions

AEGR (NASDAQ:AEGR) posted its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $1.14. The firm's revenue for the quarter was down 39.9% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that AEGR investors own include Bristol-Myers Squibb (BMY), Allergan (AGN), Ford Motor (F), Gilead Sciences (GILD), NVIDIA (NVDA), Tesla (TSLA) and Ariad Pharmaceuticals (ARIA).

Company Calendar

Last Earnings
5/16/2016
Today
6/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AEGR
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:AEGR) was last updated on 6/3/2025 by MarketBeat.com Staff
From Our Partners